Influence of methylene tetrahydrofolate reductase C667T gene polymorphism on survival time of adanced gastric cancer patients treated with 5-fluorouracil-based chemotherapy

Objective To study the methylene tetrahydrofolate reductase (MTHFR) C667T gene polymorphism and the therapeutic effect of 5-fluorouracil (5-Fu)-based chemotherapy for adanced gastric cancer patients.Methods Fifty-nine cases of pathologically diagnosed adanced gastric cancer were collected.Peripheral venous blood of all patients was drawn before chemotherapy,and DNA was extracted,and then the MTHFR genotype was detected with ligase detection reaction (LDR).All patients were treated with 5-Fu-based combined chemotherapy.Results Progression-free survival (PFS) of adanced gastric cancer patients with MTHFR T/T genotype was significantly longer than that of patients with MTHFR C/C genotype (8.70 months vs.5.47 months,x2 =9.209,P ＜ 0.01),and that of patients with MTHFR T/T genotype was significantly longer than that of patients with MTHFR C/T genotype (8.70 months vs.5.08months,x2 =9.405,P ＜0.01).There was no significant difference in PFS between patients with MTHFR C/T genotype and those with MTHFR C/C genotype (5.47 months vs.5.08 months,x2 =O.092,P ＞0.05).Conclusion MTHFR genotype has good clinical significance for predicting the therapeutic effect of 5-Fu-based chemotherapy for adanced gastric cancer. Key words: Gastric cancer;  Methylenete trahydrofolate reductase ;  Gene polymorphism; Chemotherapy